

Danusertib

Catalog No: tcsc0152



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

827318-97-8

Formula:

$C_{26}H_{30}N_6O_3$

Pathway:

Cell Cycle/DNA Damage;Epigenetics;Autophagy

Target:

Aurora Kinase;Aurora Kinase;Autophagy

Purity / Grade:

>98%

Solubility:

DMSO : 7.5 mg/mL (15.80 mM; Need ultrasonic and warming)

Alternative Names:

PHA-739358

Observed Molecular Weight:

474.55


Product Description

Danuserib is a pyrrolo-pyrazole and **aurora kinase** inhibitor with **IC₅₀** of 13, 79, and 61 nM for Aurora A, B, and C, respectively.

IC50 & Target: IC50: 13 nM (Aurora A), 79 nM (Aurora B), 61 nM (Aurora C)^[1]

In Vitro: Danuserib (0.01 to 50 μ M) significantly decreases viability of C13 and A2780cp cells. The IC₅₀s are 10.40 and 1.83 μ M for C13 cells, and 19.89 and 3.88 μ M for A2780cp cells after 24- and 48-h treatment. Danuserib induces cell cycle arrest in G2/M phase in C13 and A2780cp cells. Danuserib treatment results in a marked increase in the percentage of cells arrested in G2/M phase and an accumulation of polyploidy in C13 and A2780cp cells. Danuserib demotes the expression of CDK1/CDC2 and cyclin B1 but promotes the expression of p21 Waf1/Cip1, p27 Kip1, and p53. Danuserib induces autophagy in C13 and A2780cp cells with the involvement of PI3K/Akt/mTOR signaling pathway^[1]. PHA-739358 strongly inhibits proliferation of all leukemic cell lines tested, with IC₅₀ values ranging from 0.05 μ M to 3.06 μ M. PHA-739358 induces antiproliferative effects in BaF3-p210 cells, including IM-resistant M351T, E255K, and T315I mutants. PHA-739358 (5 μ M) reduces phosphorylation of CrkL in BaF3-p210 wt cells and IM-resistant mutants^[2]. Danuseribsertib leads to cell-cycle arrest and completely inhibits cell proliferation of the GEP-NET cells in vitro^[3].

In Vivo: PHA-739358 (15 mg/kg twice a day, i.p.) and IM are well tolerated, and significantly inhibit proliferation of K562 cells and virtually suppressed tumor growth during the 10-day treatment period^[2]. In a subcutaneous murine xenograft model, danuseribsertib (2 \times 15 mg/kg/d, i.p.) significantly reduces tumor growth in vivo compared with controls or mice treated with streptozotocine/5-fluorouracil^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!